Monarch Capital Management Inc. Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Monarch Capital Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.1% during the first quarter, according to its most recent filing with the SEC. The firm owned 44,689 shares of the biopharmaceutical company's stock after selling 2,390 shares during the period. Gilead Sciences accounts for about 1.4% of Monarch Capital Management Inc.'s portfolio, making the stock its 28th largest position. Monarch Capital Management Inc.'s holdings in Gilead Sciences were worth $5,007,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Bridgewater Associates LP increased its position in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the period. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares in the last quarter. Ontario Teachers Pension Plan Board boosted its holdings in shares of Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after buying an additional 13,086 shares in the last quarter. Mufg Securities Americas Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $1,699,000. Finally, Convergence Investment Partners LLC boosted its holdings in shares of Gilead Sciences by 15.8% in the 4th quarter. Convergence Investment Partners LLC now owns 68,447 shares of the biopharmaceutical company's stock valued at $6,322,000 after buying an additional 9,330 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

NASDAQ GILD traded up $2.75 on Thursday, hitting $112.05. The company had a trading volume of 7,023,598 shares, compared to its average volume of 7,745,913. The company has a market capitalization of $139.38 billion, a PE ratio of 302.84, a PEG ratio of 0.71 and a beta of 0.29. The company's fifty day moving average price is $105.54 and its 200-day moving average price is $102.06. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 12-month low of $62.69 and a 12-month high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The firm's revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.32) EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is presently 66.53%.

Insider Buying and Selling

In other news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares of the company's stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,000 shares of company stock valued at $4,630,310. 0.27% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target on the stock. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Piper Sandler raised their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, BMO Capital Markets lifted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.